Stockscreener 앱 받기
71.44
6.71%
4.49
시간 외 거래:
71.37
-0.07
-0.10%
전일 마감가:
$66.95
열려 있는:
$66.71
하루 거래량:
11.07M
Relative Volume:
2.27
시가총액:
$27.57B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
30.55
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
+21.97%
1개월 성능:
+10.55%
6개월 성능:
+22.29%
1년 성능:
-18.20%
1일 변동 폭
$66.30
$71.48
1주일 범위
$57.66
$71.48
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
71.44 | 25.12B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
88.38 | 153.12B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
321.49 | 120.08B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.15 | 99.27B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.67 | 83.12B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.97 | 47.44B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Dexcom stock (US2521311074): Insider sale adds focus on shares - AD HOC NEWS
Dexcom stock (US2521311074): Insider sale and sharp price jump put CGM specialist in focus - AD HOC NEWS
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany - Zacks Investment Research
Devon Energy Corp stock (US2521311074): earnings momentum and oil price tailwinds in focus - AD HOC NEWS
A Look at DexCom Inc (DXCM) After 5.6% Gain -- GF Value $102.05 vs Price $65.09 - GuruFocus
Dexcom Inc. stock (US2521311074): buyback, 2030 targets and activist deal fire up DXCM - AD HOC NEWS
DexCom : Operations and Innovation Committee - marketscreener.com
DexCom Inc. stock outperforms competitors on strong trading day - MSN
DexCom, Inc.Common Stock (NQ: DXCM - The Chronicle-Journal
A Potential Turnaround Stock In Digital Healthcare - Good Money Guide
Here's why you should hold DexCom stock in your portfolio for now - MSN
DexCom (DXCM) Introduces Dexcom Flex for Type 2 Diabetes Patients - GuruFocus
Dexcom stock (US2521311074): Analyst moves follow Elliott deal and new long-term targets - AD HOC NEWS
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany - 01net
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces - GuruFocus
DexCom Stock Jumps As 2030 Targets Ignite Bullish Trading - StocksToTrade
Dexcom Reveals Flex CGM for Type 2 Diabetes Patients - Medical Product Outsourcing
DexCom, Inc. Stock 12‑Month Price Target Cut to $82.28, Implies 34% Upside - TradingView
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo - Yahoo Finance
Elliott strikes Dexcom board settlement after taking stake - MSN
BofA Securities Adjusts Price Target on DexCom to $80 From $100 - marketscreener.com
DexCom Expands CGM Access in Germany With New Dexcom Flex System for Type 2 Diabetes - marketscreener.com
DexCom Stock Jumps After Diabetes Management Firm Reaches Agreement With Elliott Investment Management - TIKR.com
DexCom, Inc. (DXCM) Stock Analysis: 33.77% Potential Upside Attracts Investor Attention - DirectorsTalk Interviews
Dexcom Inc. stock (US2521311074): diabetes tech player in focus after recent share move - AD HOC NEWS
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - MSN
DexCom, Inc. (DXCM) Analyst/Investor DaySlideshow (NASDAQ:DXCM) 2026-05-17 - Seeking Alpha
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
symbol__ Stock Quote Price and Forecast - CNN
Stephens Investment Management Group LLC Boosts Stock Position in DexCom, Inc. $DXCM - MarketBeat
Assessing DexCom (DXCM) Valuation After Investor Day Targets And New US$1b Buyback Plan - Yahoo Finance
Did New Long-Term Targets and US$1 Billion Buyback Just Shift DexCom's (DXCM) Investment Narrative? - Yahoo Finance
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day - sharewise.com
DexCom Stock Jumps As 2030 Growth Targets And Buybacks Ignite Bullish Momentum - timothysykes.com
DexCom (DXCM) Unveils Ambitious Financial Targets and Share Repu - GuruFocus
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DNB Asset Management AS Boosts Position in DexCom, Inc. $DXCM - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Sells 98,913 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom (DXCM) Posts Upbeat 2026, Climbs 6.6% - Insider Monkey
DexCom Inc (DXCM) Shares Surge 6.6% -- What GF Score of 88 Tells Investors - GuruFocus
What Does Rep. Khanna's Spouse's DXCM Trade Signal for Diabetes Tech - Kavout
Michael Brown reports two 1,700-share DXCM sales through Morgan Stanley (DXCM) - Stock Titan
Dexcom to add 2 board directors with activist investor Elliott - MedTech Dive
DexCom (DXCM) Shares Rise 5.5% Amid Market Decline - GuruFocus
DexCom (DXCM) Is Trending on Elliott’s Deal, but Execution Is Still the Real Story - AlphaStreet
Diabetes Tech Player DexCom Lays Out 2030 Growth VisionDexCom (NASDAQ:DXCM) - Benzinga
Dexcom, Inc. (DXCM) 8-K SEC Filing Details: Company Info, Address, and Trading Information (May 14, 2026) - Minichart
Why is DexCom stock surging today? By Investing.com - Investing.com Canada
DexCom Long-Range Plan Establishes Respectable Base Case, RBC Says - Moomoo
Elliott Takes Dexcom Stake in Bet on Glucose Monitors Market - Bloomberg.com
DexCom DXCM Draws Bullish Analyst Wave As Governance Shifts - timothysykes.com
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.61%
자본화:
|
볼륨(24시간):